Objective To evaluate the therapeutic effect and benefit achieved on patients with hepatic carcinoma after live donor liver transplantation（LDLT）based on medium- and long-term follow-up experience. Methods Patients who underwent LDLT for primary hepatic carcinoma between May 2007 and April 2011 in the Department of Liver Surgery of Ren Ji Hospital in Shanghai were enrolled into this study，the clinical pathological data，perioperative outcomes，postoperative complications and follow-up results were retrospectivelyreviewed from liver transplantation database. Results From May 2007 to April 2011，there were a total of 41 patients with pathologically proven primary hepatic carcinoma underwent LDLT in our center，with 35 males（85.4％） and 6 females（14.6％），mean age of 50（28-66）years. All of the patients underwent LDLT，and were diagnosed with primary liver cancer by pathology. Salvage LDLT was performed in 3 patients（7.3%），and 13 cases（31.7％）received downstaging before LDLT. 24 of them（58.5%）met the Milan criteria，and 17 case（41.5％）exceeded the criteria. Postoperative complications happened in this group of patients included postoperative infections（13 cases，31.7％），biliary complications（11 cases，26.8％），vascular complications（1 case，2.4％），intra-abdominal bleeding（1 case，2.4％），multiple organ dysfunction syndrome（MODS，1 case，2.4％），hypertension（1 case，2.4％），mental symptom（1 case，2.4％），wound infection（3 cases，7.3％）and wound dehiscence（1 case，2.4％）. Perioperative death occurred in 1 patient（2.4％）. Overall 1- and 5-year cumulative survival rates were 90.1% and 72.3%，respectively ；and 1- and 5-year cumulative recurrence rates were 20.9% and 29.0%，respectively. 1- and 5-yearsurvival rates in 24 cases meeting Milan criteria and 17 exceeding Milan criteria were 91.7％ vs. 87.5％ and 83.1％ vs. 56.3％（P ＝ 0.051）；and 1- and 5-year cumulative survival rates were 13.0％ vs. 32.7％ and 17.4％ vs. 47.0％ （P ＝ 0.035） Conclusion Patients with primary hepatic carcinoma could achieve favorable outcomes after LDLT.

Objective To explore the role of CCL21/CCR7 signaling pathway in renal allograft fibrosis. Methods Specimens from 78 patients with creatinine increasing after kidney transplantation werecollected from kidney transplantation center of Jilin University，followed by the pathological diagnosis of the biopsyspecimens using hematoxylin-eosin（HE）staining，periodic acid-Schiff（PAS）staining and Masson staining. Thenthe immunohistochemistry staining was performed to detect the expressions and localizations of FSP，CCL21, andCCR7 respectively. Results All cases were diagnosed by HE，Masson and PAS staining，which included 13 casesof acute rejection，6 cases of vascular rejection，8 cases of chronic rejection，13 cases of boundary lesion，4 cases of nephropathy relapse，2 cases of tubular lesion，2 cases of other lesion and 30 cases of normal. Immunohistochemistry staining showed that the number of FSP+ interstitial cells in acute rejection group were more than relative normalgroup（P ＜ 0.01），and the number of FSP+ interstitial cells in chronic rejection group were more than boundarylesion group and relative normal group（P ＜ 0.05 and P ＜ 0.01）. There was no statistical significance in FSP + interstitial cells among other types of pathological changes（all P ＞ 0.05）. The result showed that the number of fibroblast in inflammatory areas were more than other areas. CCR7 positive fibroblast cells had increased terndency in chronic rejection group. CCR7 were observed in wall of blood vessel and some atrophic renal tubule and renal interstitium. CCL21 were observed in renal tubular epithelial cells and some fibroblast cells. There were no statisticalsignificance for the expression of FSP，CCR7 and CCL21 in all pathological groups（all P ＞ 0.05）. The expressionsof CCR7 and CCL21，FSP and CCL21 were observed in renal tubule and fibroblast. Conclusions Some cytokins canstimulate the cytoactivity of fibroblast in inflammation microenvironment. Patients who underwent the acute rejection in early stage after allograft kidney transplantation are more likely to suffer the reoccurrence of the chronic rejection than those who don't . CCR7/CCL21 signaling has important role in fibrosis of allograft kidney.

Objective To evaluate the efficacy and safety of bicyclol treatment in drug-induced liver injuryafter renal transplantation. Methods A retrospective analysis was performed on 36 cases of renal transplantation， who experienced drug-induced liver injury 3 months after transplantation from January 2010 to August 2013 in Second People's Hospital of Shanxi Province. 22 cases from October 2011 to August 2013 were served as test group （treated with bicyclol 25 mg/50 mg）, while 14 cases from January 2010 to September 2011 as control group（treated with capsule of Gan Caosuaneran 150 mg）. The patients in two groups received treatment 3 times per day for 4 weeks.Before and 4 weeks after treatment, the changes in alanine aminotransferase（ALT）, aspartateaminotransferase （AST）, total bilirubin（TBil）and serum creatinine（SCr）were recorded，as well as 50% decreased time and restore tonormal time of ALT. Adverse reaction induced by drugs was observed. Results ALT，AST and TBil after treatment in both groups were significantly lower than those before treatment（all P ＜ 0.05），but there was no significant change in SCr. There were no significant differences in above indexes before and after treatment between two groups （all P ＞ 0.05）. The average time of 50％ decrease in ALT and the time of return to normal in test group were significantly shorter than those in control group〔time of decreased 50％（days）：5.30±2.26 vs. 11.00±5.36，timeof return to normal（days）：7.60±4.71 vs. 16.00±9.71，both P ＜ 0.05〕. During treatment，there was no rejectionor drug-related adverse reaction in both groups. Conclusion The efficacy of bicyclol treatment on drug-induced liver injury after renal transplantation is precise，safe，and easy to use。

Objective To summarize the experiences of back-stage procedures for living donor liver graft，and to provide the experience of liver transplantation. Methods The data from 230 cases of back-stage proceduresof living donor graft in Tianjin First Center Hospital from September 2006 to May 2009 were reprospectivelyreviewed. Results A total of 230 grafts were harvested．Graft type included ：right liver graft with the middle hepatic vein in 117 cases，the inferior right hepatic vein（IRHV）was reconstructed in 5 out of 117 cases，with partial middle hepatic vein in 3 cases ；right liver graft without the middle hepatic vein in 102 cases，the IRHV wasreconstructed in 16 out of 102 cases ；left liver graft with the middle hepatic vein and caudate in 3 cases ；left lateral lobe in 2 cases. There was significant difference between two group（P ＝ 0.045）. In 102 cases of right liver graft without the middle hepatic vein ：right hepatic vein（RHV）in 11 case，RHV+ IRHV in 6 cases，RHV+V5/8 in 71cases，RHV+V5/8+IRHV in 10 cases，V5/8 in 81 cases. In some cases different materials were used to reconstructthe hepatic vein ：including cold-storage cadaveric iliac veins in 77 cases，great saphenous vein in 1 case，varicose umbililical vein in 1 case，recipient intrahepatic portal vein in 1 case and recipient intrahepatic vein in 1 case. Amongthe 222 right grafts，type C portal vein was identified in 9 cases and venoplasty was performed to incorporate 2 portal veins into a single orifice．1 case of type D was venoplastied into one orifice with iliac vein. There were 226 caseswith single hepatic artery and 4 cases with two hepatic artery. Conclusion The venoplasty and reconstruction of donor graft hepatic artery，portal vein and outflow in the protection of preservation solution can simplify implanted procedure，preserve hepatic function and it is important for postoperative recovering of the recipients．